Heinz Ludwig, MD, Wilhelminen Cancer Research Institute, Vienna, Austria, discusses the evolving role of autologous stem cell transplantation (autoSCT) in multiple myeloma (MM), outlining the challenges that have arisen over the years and the methods that have been used to overcome them. Prof. Ludwig also reveals that there is no significant difference in overall survival (OS) between patients who undergo immediate autoSCT induction and delayed induction and considers whether double transplantation could be a valuable option in subgroups of high-risk patients. This interview took place at the 21st International Myeloma Society (IMS) Annual Meeting, held in Rio de Janeiro, Brazil.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
